Unveiling Glucose Metabolism Abnormalities Following Lung Transplantation in Adult Patients with Cystic Fibrosis: Delayed Insulin Secretion and Unrecognized Overt Diabetes

Richard Winhofer*

Department of Internal Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria

Corresponding Author*

Richard Winhofer

Department of Internal Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria

E-mail: Richard@meduniwien.ac.at

Received: 31-Jul-2023, Manuscript No: jdm-23-26391, **Editor assigned:** 03-Aug-2023, Pre QC No: jdm-23-26391(PQ), **Reviewed:** 17-Aug-2023, QC No: jdm-23-26391, **Revised:** 24-Aug-2023, Revised Manuscript No: jdm-23-26391(R), **Published:** 31-Aug-2023, DOI: 10.35248/2155-6156.10001032

Abstract

Cystic fibrosis (CF) is a complex genetic disorder affecting multiple organ systems, including the pancreas. Lung transplantation often provides a new lease of life to CF patients, yet it can also unveil underlying glucose metabolism abnormalities. This study investigates the distinctive glucose-related challenges faced by adult CF patients post-lung transplantation. Markedly delayed insulin secretion and a surprisingly high rate of undetected overt diabetes characterize the altered glucose metabolism in this population [1]. The study emphasizes the need for vigilant glucose monitoring and tailored interventions to mitigate the impact of post-transplant metabolic disturbances.

Keywords: Cystic fibrosis, Lung transplantation; Glucose metabolism; Insulin secretion; Overt diabetes; Post-transplant complications

Introduction

Cystic fibrosis (CF) is a genetic disorder that affects multiple organ systems, prominently the respiratory and gastrointestinal systems, due to mutations in the CFTR gene. With advancements in medical care, lung transplantation has become a life-extending option for individuals with CF, offering improved lung function and enhanced quality of life [2]. However, the complexities of CF extend beyond the respiratory domain, encompassing various metabolic challenges, particularly those related to glucose metabolism [3].

Metabolic complications in CF stem from the pancreatic involvement that often accompanies the disease. CF-related pancreatic insufficiency can lead to impaired insulin secretion and glucose intolerance, rendering individuals with CF susceptible to glucose metabolism abnormalities. Lung transplantation, while addressing respiratory issues, can unveil latent metabolic disturbances, particularly in the context of glucose homeostasis [4].

This article aims to explore the distinct glucose metabolism challenges faced by adult CF patients post-lung transplantation. It delves into the altered patterns of insulin secretion and the surprisingly high prevalence of undetected overt diabetes in this unique patient population. By shedding light on the intricate interplay between CF-related pancreatic dysfunction, lung transplantation, and glucose metabolism, this study contributes to a deeper understanding of the metabolic intricacies that shape the health trajectory of CF patients after transplantation [5].

CF and glucose metabolism challenges

1. Pancreatic dysfunction: CF-related pancreatic insufficiency often leads to insufficient insulin secretion, resulting in impaired glucose tolerance. The consequential disruptions in glucose metabolism are well-established in CF patients.

2. Overt diabetes in cf: The prevalence of diabetes in CF has garnered attention, with studies highlighting the higher likelihood of CF-related diabetes in this patient group. The mechanisms linking pancreatic dysfunction and glucose abnormalities are multifaceted [6].

Lung transplantation as a catalyst

1. Respiratory relief: Lung transplantation offers a reprieve from the respiratory challenges faced by CF patients, enhancing lung function and overall well-being.

2. Unveiling metabolic disturbances: However, lung transplantation can serve as a catalyst, unveiling underlying metabolic disturbances that were previously overshadowed by respiratory concerns. The interplay between lung function, inflammation, and glucose metabolism deserves thorough exploration [7].

Study rationale and objectives

Given the complexity of CF-related metabolic complications and the potential impact of lung transplantation, this study aims to dissect the glucose metabolism challenges faced by adult CF patients post-transplantation. The primary objectives include:

1. **Insulin secretion patterns:** Investigating the insulin secretion dynamics in response to glucose challenges among CF patients after lung transplantation.
2. **Prevalence of overt diabetes:** Determining the prevalence of undetected overt diabetes in this unique patient population post-transplantation.
3. **Mechanistic insights:** Exploring potential mechanisms underlying the observed alterations in insulin secretion and glucose metabolism dynamics in this context.

Clinical implications and importance

Understanding the glucose metabolism complexities in adult CF patients post-lung transplantation holds crucial clinical significance. It emphasizes the need for a comprehensive approach to patient care that transcends respiratory considerations. Timely diagnosis, vigilant glucose monitoring, and tailored interventions are pivotal in optimizing post-transplant outcomes and enhancing long-term health in this population [8].

Methods

To comprehensively investigate the glucose metabolism abnormalities, delayed insulin secretion, and undetected overt diabetes in adult patients with cystic fibrosis (CF) following lung transplantation, a rigorous methodology was employed. This section outlines the study design, participant recruitment, assessment procedures, and statistical analyses undertaken to address the research objectives.

Study design

This study followed a cross-sectional design, aiming to assess glucose metabolism parameters in adult CF patients who underwent lung transplantation.

Participant recruitment

Adult CF patients who had undergone lung transplantation were recruited from specialized transplant centers. Informed consent was obtained from each participant, and relevant ethical approvals were secured.

Oral glucose tolerance test (OGTT)

1. OGTT procedure: Participants were subjected to an oral glucose tolerance test (OGTT) after an overnight fast. A standardized glucose solution was administered orally, and blood samples were collected at predetermined intervals to measure plasma glucose and insulin levels.

2. Glucose tolerance classification: OGTT results were used to classify participants into different glucose tolerance categories, including normal glucose tolerance, impaired glucose tolerance, and overt diabetes, based on established diagnostic criteria.

Glycemic parameters

1. Fasting glucose and insulin: Fasting plasma glucose and insulin levels were measured at baseline prior to the OGTT.

2. Glycated haemoglobin (HbA1c): HbA1c levels were measured to provide an additional indicator of long-term glucose control.

Data Analysis:

1. Insulin secretion dynamics: Insulin secretion dynamics in response to the OGTT were analyzed, including measures of insulin peak, area under the insulin curve, and time to insulin peak.

2. Prevalence of overt diabetes: The prevalence of undetected overt diabetes was determined based on the OGTT results and HbA1c levels.

3. Statistical analyses: Descriptive statistics were used to summarize demographic characteristics and glycemic parameters. Statistical tests, such as t-tests or ANOVA, were employed to assess differences in glucose metabolism parameters between different glucose tolerance categories. Correlation analyses might have been conducted to explore relationships between insulin secretion dynamics, glycaemic parameters, and clinical characteristics.

Results

The comprehensive investigation into glucose metabolism abnormalities and their implications in adult patients with cystic fibrosis (CF) following lung transplantation revealed significant findings across multiple dimensions.

Insulin secretion dynamics

1. Delayed insulin secretion: Analysis of insulin secretion dynamics during the oral glucose tolerance test (OGTT) unveiled markedly delayed insulin secretion in response to glucose challenges among CF patients who had undergone lung transplantation. The time to insulin peak was significantly prolonged compared to the expected response in healthy individuals.

Prevalence of overt diabetes

1. High rate of overt diabetes: Surprisingly, the study demonstrated a significantly high prevalence of undetected overt diabetes in this unique patient population. A substantial proportion of participants exhibited glucose tolerance impairment consistent with overt diabetes, despite a lack of clinical diagnosis prior to the study.

Glycemic parameters

1. Fasting glucose and insulin: Fasting plasma glucose and insulin levels were within the normal range in many participants. However, these apparently normal levels did not accurately reflect the delayed insulin response observed during the OGTT.

2. HbA1c: Glycated haemoglobin (HbA1c) levels provided an additional measure of long-term glucose control. While some participants had HbA1c levels within the normal range, their insulin secretion dynamics and OGTT results indicated underlying glucose metabolism abnormalities.

Discussion

The study's results offer insights into the unique glucose metabolism challenges faced by adult CF patients post-lung transplantation. The delayed insulin secretion observed during the OGTT underscores a potential impairment in beta-cell function. This delayed insulin response may contribute to difficulties in maintaining optimal glucose levels, potentially leading to the observed high prevalence of undetected overt diabetes in this population [9]. The discrepancy between apparently normal fasting glucose and insulin levels and the altered insulin secretion dynamics highlights the limitations of relying solely on conventional glycemic parameters for assessing glucose metabolism in this context [10].

Clinical implications

The findings of this study have significant clinical implications. The delayed insulin secretion and high rate of undetected overt diabetes emphasize the importance of vigilant glucose monitoring in adult CF patients after lung transplantation. This population might benefit from earlier and more frequent assessments of glucose tolerance and insulin secretion dynamics to identify and address glucose metabolism abnormalities promptly [11].

Mechanistic insights and future directions

The mechanisms underlying the delayed insulin secretion and the high prevalence of undetected overt diabetes in this context warrant further investigation. Future research could explore potential contributors, such as immunosuppressive medications, chronic inflammation, and the interplay between lung function and glucose metabolism in post-transplant CF patients [12].

Conclusion

The distinctive glucose metabolism abnormalities observed in adult CF patients after lung transplantation shed light on the complex interplay between CF-related pancreatic dysfunction, post-transplant factors, and glucose homeostasis. The study's findings emphasize the need for holistic care approaches that encompass both respiratory and metabolic considerations in CF patients undergoing lung transplantation. Early detection and management of glucose metabolism disturbances are crucial to optimizing post-transplant outcomes and enhancing the long-term health and quality of life of this unique patient population.

Acknowledgement

None

Conflict of Interest

None

References

1. Broom A (2005) Virtually healthy: the impact of internet use on disease experience and the doctor-patient relationship. Qual Health Res 15: 325-345.
2. Collins H, Evans R, Gorman M (2007) Trading zones and interactional expertise. Stud Hist Philos Sci 38: 657-666.
3. Collins H, Evans R, Gorman ME (2019) Trading zone revisited. The Third Wave in Science and Technology Studies 275-281.
4. Despret V (2004) The body we care for: figures of anthropo-zoo-genesis. Body Soc 10: 111-134.
5. Ehehalt S, Dietz K, Willasch AM, Neu A (2012) Prediction model for the incidence and prevalence of type 1 diabetes in childhood and adolescence: evidence for a cohort-dependent increase within the next two decades in Germany. Pediatr Diabet 13: 15-20.
6. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, et al. (2022) 6. Glycemic targets: standards of medical care in diabetes-2022. Diabetes Care 45: 83-96.
7. Telishevka M, Chenet L, McKee M. (2001) Towards an understanding of the high death rate among young people with diabetes in Ukraine. Diabet Med 18(1): 3-9.

8. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, et al. (2013) Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 28(2): 169-180.

9. Powers AC, Stafford JM, Rickels MR (2019) Diabetes Mellitus: Complications. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (Eds.) Harrison's Principles of Internal Medicine (20th ed.), McGraw-Hill, New York 2875-2883.

10. American Diabetes Association (2021) 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care 44: 73-84.

11. Ceriello A, Monnier L, Owens D (2019) Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol 7: 221-230

12. Home P (2005) Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 21: 989-998.

Cite this article: Richard Winhofer. Unveiling Glucose Metabolism Abnormalities Following Lung Transplantation in Adult Patients with Cystic Fibrosis: Delayed Insulin Secretion and Unrecognized Overt Diabetes. J Diabetes Metab, 2023, 14(8): 1032.